Adiponectin and chronic kidney disease.
Enhanced chronic inflammation and reduced insulin sensitivity are often present in chronic kidney disease (CKD). Cardiovascular disease remains a major cause of morbidity and mortality in end-stage renal patients. Adiponectin (ADP) is a hormone exclusively produced by adipocytes and possesses anti-inflammatory and cardioprotective properties. Despite the high prevalence of insulin resistance and cardiovascular disease, levels of ADP are increased among end-stage renal disease patients on hemo or peritoneal dialysis but also among patients with moderate renal failure or with the nephrotic syndrome. Furthermore, lower ADP levels are associated with poor cardiovascular outcome. In this review, we examine ADP modifications in CKD and discuss the different factors that may have an impact on this adipokine metabolism in renal failure.
Guebre-Egziabher
Fitsum
F
Département de Néphrologie, Hôpital E. Herriot, Lyon, France.
Drai
Jocelyne
J
Fouque
Denis
D
D052242:Adiponectin / Q000378:metabolism* / Q000502:physiology; D002318:Cardiovascular Diseases / Q000378:metabolism; D002908:Chronic Disease; D006801:Humans; D007249:Inflammation / Q000378:metabolism; D007674:Kidney Diseases / Q000378:metabolism*; D024821:Metabolic Syndrome / Q000378:metabolism
D052242:Adiponectin